Skip to main content
TipRanks
Go Ultimate75% OFF

Oncolytics Biotech (ONCY) Drug Pipeline

1,677 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Bevacizumab, Folfiri, PelareorepMcrc, Ras-Mutated Metastatic Colorectal Cancer, Mss Metastatic Colorectal CancerPhase IINot Yet RecruitingFOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerFeb 25, 2026
Atezolizumab, Pelareorep, Gemcitabine And Nab-Paclitaxel, Trifluridine Tipiracil, Mfolfirinox Treatment RegimenPancreatic Cancer Metastatic, Anal Cancer Metastatic, Squamous Cell Carcinoma Of The Anus Stage Unspecified, Unresectable Pancreatic Carcinomaphase1AndPhase2Active Not RecruitingA Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabNov 18, 2025―
Paclitaxel, Avelumab, PelareorepBreast Cancer MetastaticPhase IIActive Not RecruitingA Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyDec 24, 2019―
Trastuzumab, Letrozole, Atezolizumab, PelareorepBreast CancerearlyPhase1TerminatedA Window-of-opportunity Study of Pelareorep in Early Breast CancerSep 23, 2019―
Gemcitabine, Cisplatin, ReolysinMuscle-Invasive Transitional Cell Carcinoma Of The BladderPhase IWithdrawnStudy of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the BladderMar 24, 2016―
Leucovorin, Gemcitabine, Pembrolizumab, Irinotecan, 5-Fluorouracil, Reolysin, ChemotherapyPancreatic AdenocarcinomaPhase ICompletedStudy of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaNov 25, 2015―
Bevacizumab, Leucovorin, Irinotecan, Reolysin, FluorouracilKras Mutant Metastatic Colorectal CancerPhase ICompletedStudy of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal CancerJan 07, 2011―
Carboplatin, Paclitaxel, ReolysinMetastatic Or Recurrent Squamous Cell Carcinoma Of The LungPhase IICompletedA Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the LungOct 15, 2009―
Carboplatin, Paclitaxel, ReolysinCarcinoma, Non-Small Cell LungPhase IICompletedPhase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR ActivationMar 12, 2009―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oncolytics Biotech (ONCY) have in its pipeline
Oncolytics Biotech ONCY is currently developing the following drugs: Bevacizumab, Folfiri, Pelareorep, Atezolizumab, Pelareorep, Gemcitabine And Nab-Paclitaxel, Trifluridine Tipiracil, Mfolfirinox Treatment Regimen, Paclitaxel, Avelumab, Pelareorep, Trastuzumab, Letrozole, Atezolizumab, Pelareorep, Gemcitabine, Cisplatin, Reolysin, Leucovorin, Gemcitabine, Pembrolizumab, Irinotecan, 5-Fluorouracil, Reolysin, Chemotherapy, Bevacizumab, Leucovorin, Irinotecan, Reolysin, Fluorouracil, Carboplatin, Paclitaxel, Reolysin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.